PP106 KBI Website Homepage Banner BG V15


Exploring New Peaks in Biophysical Characterization
Hosted by Applied Photophysics and KBI
May 9, 2024
Louisville, Colorado


John F. Carpenter 

Professor Emeritus of Pharmaceutical Sciences at the University of Colorado School of Pharmacy 

Talk: Adverse Immunogenicity of Protein Drugs: Roles for Aggregates/Particles and Inadequate Analytical Methods

John F. Carpenter, Ph.D. is Professor Emeritus of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a Co-Founder and former Co-Director of the University of Colorado Center for Pharmaceutical Biotechnology. His research interests include mechanisms for protein degradation and stabilization in pharmaceutical formulations, during bioprocessing and in drug delivery systems. Also, he has worked for several years to define rational strategies for stabilizing proteins and vaccines during freeze-drying and storage in the dried solid. He has published more than 300 peer-reviewed papers and is an inventor of more than 30 issued patents. He is an Editor for Reviews and Commentaries for the Journal of Pharmaceutical Sciences. He serves on the Editorial Advisory Boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics and BioPharm International. He has received several teaching awards and The Ebert Prize. He is a Fellow of the American Association for Advancement of Science, the American Association of Pharmaceutical Scientists (AAPS) and the National Academy of Inventors, and has received the AAPS Research Achievement Award in Biotechnology. He also was a co-founder and an organizer for the Colorado Protein Stability Conferences.


Brent Kendrick

Founder and owner of First Principles Biopharma, LLC

Talk: Biophysics of sucrose-IL-1ra Interactions.

Brent Kendrick is founder and owner of First Principles Biopharma, LLC, specializing in biopharmaceutical data sciences, data analysis automation, product formulation, analytical development, and product characterization from pre-clinical development through commercial launch. He has over 28 years of experience in biologics drug development. He received his B.S in Aerospace Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Colorado. Prior to graduate school, Brent served in the United States Navy as a Surface Warfare Officer. He served at Amgen for 18 years in Formulation Development, Quality Control, Analytical Sciences and Process Development. Prior to leaving Amgen, he was Director of Amgen’s Attribute Sciences for Late Stage Clinical and Commercial Products, leading a team of over 100 staff and multiple sites worldwide through successful product development and regulatory filings. He has been an adjoint and adjunct faculty member at the University of Colorado for over 22 years, teaching Light Scattering Biophysics, Biopharmaceutical Development, and a semester-long course in Heat Transfer. He has lectured for the Massachusetts Institute of Technology (MIT) course in protein formulations. In 2015 he co-founded Elion, LLC, a contract analytical and formulations laboratory for biotechnology product development and served as Chief Scientific Officer throughout his tenure. After KBI Biopharma’s acquisition of Elion, he served as Vice President, Research and Development at KBI Biopharma until 2021, when he founded First Principles Biopharma, LLC.


Pavel Ryzhov

Senior Business Manager at WuXi Biologics

Talk: Biophysical Characterization of Fundamental Protein Questions: Folding, Physiological Conformation and Post-Translational Modifications.

Pavel Ryzhov, PhD is a Senior Business Manager at WuXi Biologics. In his role, he is responsible for the commercialization of early-stage Antibody Research services. Pavel received his PhD in Biomedical Sciences from Sanford Burnham Prebys Institute in San Diego, CA, with a focus on biophysical characterization of membrane proteins. He also previously worked as an Application Scientist at Applied Photophysics, Inc., where he leveraged his prior experience with stopped-flow kinetics from the University of Cambridge to help clients with new instrument installation and training.


Justin Hopkins 

Scientist at KBI-Biopharma

Talk: Determination of Activation Energy of Lysozyme using Differential Scanning Fluorimetry 

Justin earned his B.S. in Chemical and Biological Engineering at the University of Colorado Boulder in 2017, and just celebrated his 7-year anniversary with KBI. Justin leads the Louisville formulation development team and has also taken over leadership of the global formulation development team to align goals and strategies across all KBI sites. He is a site expert and trainer for several analytical techniques, including cIEF, osmolarity, viscosity, DLS, DSC, and JMP statistical analysis. He is particularly passionate about the application of statistics to support strategic experimental design and data interpretation. When not in lab, Justin seeks opportunities to mentor other staff, to lead client programs, and to give back to the community through coordinating volunteer opportunities such as the collaboration with Boulder County Parks and Open Space. Justin’s technical expertise, enthusiasm, and innovation mindset are key for our team’s continued excellence in formulation development and product characterization.


Arani Chanda 

Executive Director, Pharmaceutical and Early Phase Analytical Development

Talk: Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics

Arani grew up in Kolkata, India and completed his education in chemistry from Presidency College, Kolkata (B.Sc., Hons) and Indian Institute of Technology (IIT), Kanpur (M.Sc.) before joining Prof. Terry Collins’s lab at Carnegie Mellon University, Pittsburgh for his doctoral work. His studies involved mechanistic understanding and application of biomimetic TAML catalysts which is now commercially marketed by Sudoc Inc. As a Pfizer post-doctoral fellow, Arani worked with Nobel laureate Prof. K Barry Sharpless and Prof. Valerie Fokin at the Scripps Research Institute to develop novel water based synthetic pathways. He has over 15 years of professional experience in the fields of process and analytical development involving early to commercial stage products. Through progressive roles at Eisai Inc and Sarepta Therapeutics, he is currently Executive Director of Pharmaceutical and Early Phase Analytical Development leading teams on strategic projects towards development and commercialization of novel drugs for rare diseases. In addition, he serves as scientific advisor for Sudoc Inc helping to bring the family of TAML™ catalyst to market in a variety of applications.


Sign up for the Biophysical Summit